Entering text into the input field will update the search result below

Verastem submits marketing application in Europe for Copiktra

  • Verastem (NASDAQ:VSTM) submits marketing authorization application (MAA) to the European Medicines Agency (EMA) for COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), seeking approval for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and relapsed or refractory follicular lymphoma.
  • Shares are up 3% premarket.

Recommended For You

About VSTM Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
VSTM--
Verastem, Inc.